Contact Us
We are building a global footprint to achieve our mission of addressing unmet medical needs
We are building a global footprint to achieve ourmission and vision
Locations
Corporate HeadquartersDenmark
Ascendis Pharma A/S
(Company Reg. No. 29918791)
United States
Ascendis Pharma, Inc.
Ascendis Pharma Endocrinology, Inc.
902 Carnegie Center Blvd
Suite 301
Princeton NJ 08540
USA
Tel: +1 609 651 8600
www.ascendispharma.us
Suite 301
Princeton NJ 08540
USA
Tel: +1 609 651 8600
www.ascendispharma.us
Germany
Ascendis Pharma GmbH
Im Neuenheimer Feld 584
D-69120 Heidelberg
Germany
Tel: +49 6221 99 89 00
Geschäftsführerin: Lotte Sønderbjerg
Amtsgericht Mannheim: HRB 337385
USt-IdNr. DE813586261
D-69120 Heidelberg
Germany
Tel: +49 6221 99 89 00
Geschäftsführerin: Lotte Sønderbjerg
Amtsgericht Mannheim: HRB 337385
USt-IdNr. DE813586261
Contacts
ADVERSE EVENT REPORTS
Report side effects or adverse events for Ascendis Pharma products
CALL:
ASCENDIS:
1-844-442-7236
(Fax 1-650-618-2723)
U.S. FDA:
1-800-FDA-1088 or
Report to FDA online
www.fda.gov/medwatch
1-844-442-7236
(Fax 1-650-618-2723)
U.S. FDA:
1-800-FDA-1088 or
Report to FDA online
www.fda.gov/medwatch
BUSINESS DEVELOPMENT
MEDIA
CAREER OPPORTUNITIES
INVESTORS
Explore
TransCon hGH (lonapegsomatropin), an investigational GHD therapy administered once weekly
